BAJAJ FINSERV DIRECT LIMITED
Open Your FREE Demat Account Now!

SMS Pharmaceuticals Ltd. Share Price

NSE
BSE

NSE : SMSPHARMA

BSE : 532815

Sector : Healthcare

N/A
indicator
1D
1M
3M
6M
1Y
5Y
empty graph

Day's Range

Day's Range

Low

₹370.15

High

₹374.10

Price Summary

Previous Close ₹370.50
Day's Range ₹370.15 - ₹374.10
Open ₹373.05
52 Week Range ₹231.00 - ₹447.80
Volume 12,077
Market Cap ₹0.00
Previous Close ₹372.00
Day's Range ₹371.00 - ₹373.50
Open ₹373.05
52 Week Range ₹230.75 - ₹446.50
Volume 984
Market Cap ₹0.00

Stocks Summary

Trade Value ( ₹ in Lacs) 44.75
Market Cap (₹ in Mn) 0.00
Dividend Yield(%) 0.11
Price/Earning (TTM) 34.12
TTM EPS (₹) 10.93
P/E Ratio 27.27
Book Value(₹) 4.33
PAT Margin (%) 7.96
Face Value (₹) 1.00
ROCE(%) 12.55
Trade Value ( ₹ in Lacs) 3.66
Market Cap (₹ in Mn) 0.00
Dividend Yield(%) 0.11
Price/Earning (TTM) 34.12
TTM EPS (₹) 10.93
P/E Ratio 27.27
Book Value(₹) 4.33
PAT Margin (%) 7.96
Face Value (₹) 1.00
ROCE(%) 12.55

Financials

Particulars QTR FY (₹ in Millions) Annual FY (₹ in Millions)
Net sales 1960.47 7827.48
Expenses N/A N/A
PBT 238.62 933.2
Operating profit 0.0 0.0
Net profit 182.08 683.81

Shareholding Pattern

Promoters (% Holding)

68.07%

Mutual funds (% Holding)

2.81%

Non-Institution (% Holding)

28.45%

FI/Banks/Insurance (% Holding)

0.00%

Government (% Holding)

0.00%

FII

0.65%

About SMS Pharmaceuticals Ltd.

Founded 1987
Managing Director Ramesh Babu Potluri
NSE Symbol SMSPHARMA

Peer Comparision

Stocks Name Market Cap (Cr)(₹) Market Price (₹) 52 Week Low-High (₹)
Sun Pharmaceutical Industries Ltd. 4,63,791.45 1,926.65 1,548.00 - 1,548.00
Divi's Laboratories Ltd. 2,45,080.59 9,262.00 5,636.50 - 5,636.50
Torrent Pharmaceuticals Ltd. 1,90,351.29 4,954.20 3,480.60 - 3,480.60
Apollo Hospitals Enterprise Ltd. 1,25,308.33 8,717.00 6,696.50 - 6,696.50
Lenskart Solutions Ltd. 1,16,281.31 672.55 0.00 - 0.00
Zydus Lifesciences Ltd. 1,14,832.64 1,150.50 835.50 - 835.50
Cipla Ltd. 1,14,162.52 1,414.95 1,165.70 - 1,165.70
Laurus Labs Ltd. 1,00,660.17 1,859.15 823.10 - 823.10
Lupin Ltd. 98,431.05 2,154.80 1,875.00 - 1,875.00
Mankind Pharma Ltd. 98,304.73 2,370.70 1,909.70 - 1,909.70
no-content No Records Found

Latest News

Sep
2
2026
EQUITY Posted on Sep 2nd 2026

SMS Pharmaceuticals informs about credit rating

Pursuant to 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, SMS Pharmaceuticals has informed that the CARE Ratings vide their letter No. CARE/HRO/RL/2026-27/1219 dated 01st September, 2026 has reaffirmed/revised its ratings assigned to the bank facilities of the Company. The company has enclosed the summary of ratings for the Company. The rating letter received from CARE Ratings (CARE) is attached as Annexure.

The above information is a part of company’s filings submitted to BSE.

Read More
Aug
29
2026
EQUITY Posted on Aug 29th 2026

SMS Pharmaceuticals informs about press release

SMS Pharmaceuticals has informed that it enclosed copies of the newspaper advertisement published on 29th August, 2026, informing the shareholders about the 38th Annual General Meeting of SMS Pharmaceuticals to be held on Tuesday, 29th September, 2026 at 10.30 am IST through Video Conference or Other Audio Visual Means, in compliance with the Circulars issued by the Ministry of Corporate Affairs (MCA) and Securities Exchange Board of India (SEBI). The advertisement has been published in the following newspapers: Financial Express (in English Language); Nava Telangana (in Telugu Language). The newspaper advertisements is also made available on the website of the Company www.smspharma.com at Investors section.
The above information is a part of company’s filings submitted to BSE.
Read More
Aug
27
2026
EQUITY Posted on Aug 27th 2026

SMS Pharmaceuticals informs about AGM

SMS Pharmaceuticals has informed that due to certain unavoidable circumstances, administrative and scheduling constraints, today the Board of Directors of the Company, have approved, change in the date of the 38th Annual General Meeting (“AGM”) of the Company and consequently the record date for determining the Members eligible to receive the dividend, and book closure dated were revised, through circulation. Accordingly, the revised schedule is as enclosed. 38th Annual General Meeting of the Company, for the financial year ended 31st March, 2026, shall now be held on Tuesday, 29th September, 2026, (instead of Wednesday, 23rd September, 2026) through Video Conferencing (“VC”) / Other Audio-Visual Means (“OAVM”), in accordance with the applicable circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India; The Register of Members and Share Transfer Books of the Company shall remain closed from Wednesday, 23rd September, 2026 to Tuesday, 29th September, 2026, (both days inclusive), for the purpose of the 38th AGM; The Company has fixed Tuesday, 22nd September, 2026 as the ‘Record Date’ (instead of Wednesday, 16th September, 2026) for determining the Members eligible to receive the dividend for the financial year 2025-26, if approved at the ensuing AGM and the same will be paid within the stipulated time period. All other items in earlier intimation dated 31st July, 2026 shall remain unchanged.
The above information is a part of company’s filings submitted to BSE.
Read More
Jul
25
2026
EQUITY Posted on Jul 25th 2026

SMS Pharmaceuticals informs about board meeting

SMS Pharmaceuticals has informed that the meeting of the Board of Directors of the Company is scheduled on 01/08/2026, inter alia, to consider and approve Un-audited Financial Results of the Company for the first quarter ended on June 30, 2026.

The above information is a part of company’s filings submitted to BSE.

Read More
Jul
22
2026
EQUITY Posted on Jul 22nd 2026

SMS Pharmaceuticals informs about newspaper publication

Pursuant to Regulations 30 and 47 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, SMS Pharmaceuticals has enclosed copies of the newspaper advertisement published on 22nd July, 2026, informing the shareholders about transfer of shares to Investor Education Protection Fund (IEPF) pertaining to the unpaid/ unclaimed dividend for the financial year 2018 -2019. The advertisement has been published in the following newspapers: Financial Express (in English language), Nava Telangana (in Telugu language). The newspaper advertisements are also made available on the website of the Company www.smspharma.com at Investors Section.
The above information is a part of company’s filings submitted to BSE.
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the current share price of SMS Pharmaceuticals Ltd. ?

The current share price of SMS Pharmaceuticals Ltd. is ₹370.50 as of 2026-09-03.

The market capitalisation of SMS Pharmaceuticals Ltd. is ₹3,493.69 as of 2026-09-02.

The 1-year return of SMS Pharmaceuticals Ltd. is 135.85% as of 2026-09-03.

The P/E ratio of SMS Pharmaceuticals Ltd. is 27.27 as of 2026-09-03.

The 52-week high and low of SMS Pharmaceuticals Ltd. are ₹447.80 and ₹231.00, respectively, as of 2026-09-03.

The dividend yield of SMS Pharmaceuticals Ltd. is 0.1072% as of2026-09-02.

You can buy SMS Pharmaceuticals Ltd. shares through a registered stockbroker or trading platform. Bajaj Markets partners with trusted brokers to help you open a demat account. This is the first step to trading, making it easier to invest in your desired shares.

The Managing Director of SMS Pharmaceuticals Ltd. is Ramesh Babu Potluri .

When investing in a company’s stock, you may consider key factors such as its fundamentals, including financial health, historical performance, and growth potential. Assess the consistency of its performance, market conditions, and industry trends. Additionally, evaluate your own risk tolerance while reviewing aspects like quarterly earnings, management quality, and sector performance, for taking a well-informed decision.

You can track stock performance on online platforms through live market updates, historical charts, and news alerts. Regular analysis and stock alerts allow you to stay informed about significant price changes and events affecting the stock.

Common stock provides voting rights and the potential for dividends based on company performance, while in case of preferred stock, stockholders receive fixed dividends and have priority over common stockholders in asset distribution but generally lack voting rights.

Stock investments carry market risks, including price volatility, economic shifts, and sector-specific issues. Managing risk can involve diversifying your portfolio, setting stop-loss orders, and staying informed about market trends to make timely decisions.

Market capitalisation, or market cap, is the total value of a company’s outstanding shares and is calculated by multiplying the stock price by the total shares. It classifies companies as large-cap, mid-cap, or small-cap, reflecting their size, stability, and potential risk level in the stock market.

View More

People Also Ask

How does SMS Pharmaceuticals Ltd. partner with other entities in the hospital and pharma sector?

SMS Pharmaceuticals Ltd. partners with the pharma sector by acting as a highly reliable, large-scale contract manufacturer. The enterprise collaborates with major global and domestic pharmaceutical companies to supply cost-effective, high-quality bulk drugs and pharmaceutical intermediates.

SMS Pharmaceuticals Ltd. produces a critical range of Active Pharmaceutical Ingredients (APIs) and advanced intermediates. The company specialises heavily in manufacturing high-volume bulk drugs for anti-ulcer, anti-fungal, and anti-retroviral therapeutic applications.

View More

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore